Turning scientific progress into market clarity
Innovative science struggles when its value can't be translated into confident decisions.
The Commercialization Translation Brief is a short, focused engagement designed to align scientific reality with commercial action, so your team, partners, and buyers understand why this product exists now and what changes because it does.
It is translation: turning what you know into what your market can act on.
What this process is designed to do
Most teams already have strong ingredients: solid data, regulatory progress, a clear mission, experienced leadership.
What's often missing is shared commercial logic.
Different functions tell different versions of the story.
Sales hesitates. Partners ask the same questions repeatedly. Decks evolve, but confidence doesn't.
The Translation Brief creates a single, decision-ready narrative your organization can stand behind.
How the process works
This engagement is intentionally structured, time-bound, and collaborative. No fishing expeditions. No endless meetings.
1. Evidence Review
Understanding what already exists. I begin by reviewing a small, targeted set of materials (typically a recent deck, validation summary, and regulatory overview) to understand how the product is currently being described across audiences.
This step surfaces early signs of misalignment, unclear assumptions, and gaps between scientific confidence and market messaging.
No revisions yet. Just pattern recognition.
2. Translation Conversations
Aligning science, regulation, and commercial reality. Next, I facilitate a small number of focused conversations, usually 3–5, across key functions (scientific/clinical, regulatory, commercial).
These are structured translation discussions designed to clarify what the data truly supports, what regulatory milestones tell buyers, where objections arise and why, and how real workflows shape adoption.
This is where clarity emerges.
3. Synthesis & Drafting
From insight to shared logic. I synthesize inputs into a concise Commercialization Translation Brief that converts evidence into decision confidence, connects regulatory progress to buyer safety, grounds innovation in real-world workflows, and names objections honestly and addresses them credibly.
The brief is written for internal alignment first, so it can power downstream execution.
4. Alignment Review
Pressure-testing before it's finalized. Before delivery, we conduct a short review to ensure the brief reflects shared reality rather than wishful thinking.
The goal is alignment for action.
What you receive
- A clear, structured Commercialization Translation Brief
- A single internal narrative teams can reference and reuse
- Guidance on what to emphasize, what to defer, and what not to lead with
- A foundation for sales enablement, partnerships, marketing, and investor communication
Most clients find this brief reduces friction across multiple functions almost immediately.
Who this is for
This engagement is best suited for teams who are preparing for commercialization or scale, have strong science but uneven market traction, or need alignment before investing in messaging, sales, or partnerships.
It is especially valuable in moments of transition: pre-launch, post-validation, regulatory inflection points, or go-to-market reset.
How it relates to other work
It sits alongside market research, brand positioning, copywriting, and clinical or regulatory strategy.
It is the connective tissue that allows those efforts to work together.
Why this approach works
Because adoption happens when people feel confident, protected, and clear.
The Commercialization Translation Brief creates that clarity without oversimplifying what matters most.
How the Commercial Translation Brief and Go-to-Market Readiness Map work together
Most commercialization efforts fail in one of two ways. Either the story is compelling, but no one knows how to move. Or the plan is ambitious, but no one is fully convinced.
The Commercialization Translation Brief and the Go-to-Market Readiness Map address these failures in sequence, by aligning meaning first, then motion.
The Translation Brief ensures your product can be explained in a way that creates confidence: clarity about why it exists now, alignment between data, regulation, and real-world use, and a narrative teams and partners can stand behind.
The Go-to-Market Readiness Map ensures that confidence can turn into action: clear buyer sequencing and decision logic, explicit understanding of adoption risk, and a realistic view of how the product moves through systems.
Together, they create a complete readiness framework. One translates scientific and regulatory progress into shared commercial logic. The other tests whether that logic can survive contact with real buyers, workflows, and constraints.
Used independently, each engagement solves a specific problem. Used together, they prevent costly misalignment before execution begins.
This pairing is especially powerful for teams approaching launch, scaling after a raise, or resetting go-to-market strategy, when clarity is essential and mistakes are expensive.